Financial Enhancement Group’s Novo Nordisk NVO Stock Holding History

Financial Enhancement Group’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-810	Closed	-$40K	–	247
2022 Q3	$40K	Hold	810	–	–	0.01%	148
2022 Q2	$45K	Hold	810	–	–	0.01%	140
2022 Q1	$45K	Buy	810 +50	+7%	+$2.57K	0.01%	141
2021 Q4	$43K	Sell	760 -40	-5%	-$2.17K	0.01%	144
2021 Q3	$38K	Hold	800	–	–	0.01%	146
2021 Q2	$34K	Hold	800	–	–	0.01%	140
2021 Q1	$27K	Hold	800	–	–	0.01%	141
2020 Q4	$28K	Hold	800	–	–	0.01%	161
2020 Q3	$28K	Hold	800	–	–	0.01%	143
2020 Q2	$26K	Hold	800	–	–	0.01%	149
2020 Q1	$24K	Hold	800	–	–	0.01%	156
2019 Q4	$23K	Hold	800	–	–	0.01%	160
2019 Q3	$21K	Hold	800	–	–	0.01%	163
2019 Q2	$20K	Hold	800	–	–	0.01%	163
2019 Q1	$21K	Buy	+800	New	+$19.7K	0.01%	177

Other funds holding NVO

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Financial Enhancement Group's NVO Position: Q4 2022 in Review

Financial Enhancement Group sold out of Novo Nordisk (NVO) in Q4 2022, closing a stake of 810 shares — an estimated $40K sold.

Financial Enhancement Group first reported a position in NVO in Q1 2019 and held it in 15 quarters. The position peaked at $45K in Q2 2022. 1,049 funds tracked by Wall St. Rank hold NVO as of Q4 2022.

Financial Enhancement Group reported no remaining Novo Nordisk position as of Q4 2022 after selling out during the quarter.
Financial Enhancement Group sold 810 Novo Nordisk shares in Q4 2022, an estimated $40K.
Financial Enhancement Group first reported a position in Novo Nordisk in Q1 2019 and held it in 15 quarters.
Financial Enhancement Group's Novo Nordisk position peaked at $45K in Q2 2022.
1,049 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2022.

Based on Financial Enhancement Group's 13F filing for Q4 2022, filed 9 Feb 2023.